# Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)

> **NCT01471379** · PHASE2 · TERMINATED · sponsor: **Spencer Dorn, MD, MPH** · enrollment: 2 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Milnacipran
- **DRUG:** Milnacipran
- **DRUG:** Milnacipran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01471379
- **Lead sponsor:** Spencer Dorn, MD, MPH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Due to recruitment difficulties the study is terminated.
- **Last updated:** 2017-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01471379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01471379, "Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01471379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*